Regulatory Burden

FASEB : OPA : Policy Issues

FASEB Policy Statements

Go Back


>	FASEB Comments on OIG Compliance Program Guidance for Recipients of PHS Research Awards January 24, 2006

>	FASEB Urges Congress to Protect the Integrity of Scientific Evidence During Rule Making November 5, 2004

>	FASEB opposes efforts to limit travel to scientific meetings October 6, 2004

>	FASEB / AAMC Respond to Steiger on WHO Technical Consultation October 6, 2004

>	FASEB and AAMC Presidents Question DHHS Policy on Technical Consultation July 20, 2004

>	FASEB Joins AAMC in Comments on Revisions to OMB Proposals for Regulatory Peer Review May 28, 2004

>	FASEB Joins AAMC in Comments on OMB Proposed Bulletin for Regulatory Peer Review December 4, 2003

>	FASEB Comments on NSTC Subcommittee on Research Business Models. October 9, 2003

>	FASEB Opposes Proposed Boycott of Research and Cultural Links with Israel June 5, 2002

>	FASEB Letter to Wendy Baldwin, Ph. D. re NIH proposed policy regarding the sharing of research data and Sample Checklist June 4, 2002

>	FASEB Letter to OMB on Draft Report to Congress on the Costs and Benefits of Federal Regulation May 16, 2002

>	FASEB Joins Coalition of Associations in Objecting to HIPAA Privacy Regulations August 14, 2001

>	FASEB President Robert R. Rich to the Office of Management and Budget on Proposed Data Quality Guidelines August 8, 2001

>	Data Quality

>	FASEB Representatives to Participate in NIH Review of Regulatory Burdens on Federally Funded Research

>	A Legal Look at the Proposed Modifications to Circular A-110

>	FASEB Reviews NIH's Report on the Effect of Regulations on Research

>	FASEB Scientists Warn Officials about the Potential Dangers of Proposed FOIA Changes

>	FASEB Asks Scientists for Input on Regulatory Burden

The Federation of American Societies for Experimental Biology (FASEB) advances biological science through collaborative advocacy for research policies that promote scientific progress and education and lead to improvements in human health.